Get Your Personalized Supplement StackSupplement Stack Quiz

OcuDyne Proprietary Blend

Also known as: OcuDyne Proprietary Blend, OPTiC System

Overview

The OcuDyne Proprietary Blend is not a conventional oral supplement but rather a component of the OPTiC System, a medical device-based intervention. This system involves ophthalmic artery angioplasty, a procedure designed to improve retinal perfusion in patients with geographic atrophy, a late-stage form of Age-Related Macular Degeneration (AMD). The blend's composition is proprietary and not publicly disclosed. The OPTiC System aims to address chronic ischemia in the ophthalmic artery, thereby enhancing oxygen and nutrient supply to the retina. Research is currently in the clinical pilot study phase, with initial results indicating procedural feasibility and safety. However, independent systematic reviews or meta-analyses specifically evaluating the blend or device are not yet available. This approach differs significantly from traditional nutritional supplements used in AMD management.

Benefits

The OcuDyne Proprietary Blend, as part of the OPTiC System, has demonstrated potential benefits in patients with geographic atrophy secondary to AMD. A pilot clinical trial reported subjective improvements in visual acuity, reading speed, and patient-reported outcomes related to mobility and independence. Objective evidence suggested preservation of visual function, inhibition of geographic atrophy growth, and increased choroidal thickness, indicating improved retinal perfusion. These benefits were observed at 6 months post-intervention. However, the evidence is preliminary, and larger, controlled trials are needed to confirm these findings and quantify effect sizes. The treatment targets patients with geographic atrophy secondary to AMD.

How it works

The OPTiC System, incorporating the OcuDyne Proprietary Blend, works by addressing chronic ischemia in the ophthalmic artery, a condition hypothesized to contribute to the progression of AMD. The intervention aims to improve retinal oxygenation and nutrient supply through ophthalmic artery angioplasty. This procedure targets the vascular system, specifically the ophthalmic artery, to alleviate atherosclerotic vascular disease implications in AMD. The mechanism focuses on improving vascular perfusion rather than targeting specific molecular pathways. By enhancing blood flow to the retina, the treatment seeks to preserve and potentially improve visual function in patients with geographic atrophy.

Side effects

The pilot study of the OPTiC System, which includes the OcuDyne Proprietary Blend, reported a positive safety profile. Common side effects were ocular adverse events related to the angioplasty procedure; these were transient and resolved without treatment. Uncommon side effects included systemic adverse events, which were expected, treated, and resolved without lasting consequences. No device-related adverse events were reported. Specific contraindications are not detailed in the available data. As the intervention is procedural, drug interactions are not applicable. Further research is needed to fully characterize the long-term safety profile and potential risks associated with the OPTiC System.

Dosage

Dosage is not applicable as the OcuDyne Proprietary Blend is part of a medical device-based procedural intervention (OPTiC System) involving ophthalmic artery angioplasty. The treatment involves a single procedural intervention, and benefits were evaluated at 6 months post-procedure. There are no minimum effective, optimal, or maximum safe doses in the traditional sense. The OPTiC System utilizes a proprietary catheter system for the angioplasty procedure. Absorption factors and required cofactors are not relevant in this context.

FAQs

Is OcuDyne Proprietary Blend an oral supplement?

No, it is a component of the OPTiC System, a medical device-based procedural treatment involving ophthalmic artery angioplasty.

Is the treatment safe?

The pilot study indicates a favorable safety profile with transient and manageable adverse events, but further research is needed.

How soon can benefits be expected?

Visual function improvements were observed within 6 months of the procedure in the pilot study.

Is there independent verification of efficacy?

Currently, no independent systematic reviews or meta-analyses specifically on OcuDyne’s blend or device exist.

Is this treatment widely available?

It is in clinical trial phases with regulatory discussions ongoing, and is not yet widely available.

Research Sources

https://ocudyne.com/ocudyne-announces-positive-results-for-the-optic-system-6-month-clinical-trial-in-the-treatment-of-geographic-atrophy/ – This press release announces positive results from OcuDyne's 6-month clinical trial of the OPTiC System for treating geographic atrophy. The trial demonstrated procedural feasibility and safety, along with improvements in visual function and anatomical markers. These findings suggest potential benefits in preserving vision and inhibiting disease progression in AMD patients.
https://www.ophthalmologytimes.com/view/ocudyne-completes-successful-pilot-study-of-optic-system – This article reports on the successful completion of OcuDyne's pilot study of the OPTiC System. The study showed that the procedure is feasible and safe, with preliminary evidence suggesting improvements in visual function. The OPTiC System aims to improve retinal perfusion by addressing ischemic conditions in the ophthalmic artery.
https://pubmed.ncbi.nlm.nih.gov/36296956/ – This systematic review and meta-analysis evaluated the effects of various supplements on AMD progression and visual function. The review found that lutein, zeaxanthin, and omega-3 fatty acids showed some benefit in slowing AMD progression and improving visual function. However, this study did not evaluate the OcuDyne blend or the OPTiC System.
https://ocudyne.com/about/in-the-news/ – This page provides a collection of news articles and press releases related to OcuDyne and its OPTiC System. These resources highlight the company's progress in developing and testing the device for treating geographic atrophy. The information presented focuses on the potential benefits and safety of the OPTiC System based on clinical trial results.
https://www.prnewswire.com/news-releases/ocudyne-announces-positive-results-for-the-optic-system-6-month-clinical-trial-in-the-treatment-of-geographic-atrophy-302242510.html – This press release details the positive outcomes of OcuDyne's 6-month clinical trial of the OPTiC System for geographic atrophy. The trial demonstrated improvements in visual acuity, reading speed, and choroidal thickness. These results suggest that the OPTiC System may offer a new approach to managing geographic atrophy by improving retinal perfusion.